热门资讯> 正文

CyclomX获得结直肠癌抗体-药物结合物快速通道地位

2026-08-27 23:34

The US FDA has granted Fast Track designation to CytomX's (CYTM) antibody-drug conjugate Varseta-M (varsetatug masetecan) for metastatic colorectal cancer.
The asset is aimed at epithelial cell adhesion molecule (EpCAM) with a topoisomerase-1 inhibitor payload.
Varseta-M is currently in phase 1. CytomX is eyeing a first registrational trial in H1 2027.

More on CytomX

CytomX Therapeutics: Promising Varseta-M With Comfortable Runway
CytomX Therapeutics, Inc. (CTMX) Q2 2026 Earnings Call Transcript
CytomX Therapeutics, Inc. (CTMX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
CytomX outlines Varseta-M registrational start in H1 2027 while projecting cash runway into H2 2028
CytomX Q2 2026 Earnings Preview

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。